NASDAQ · Biotechnology · USD
MediciNova, Inc. (MNOV) Stock Analysis
MediciNova, Inc. (MNOV) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
MNOV Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.37
- Previous Close
- $1.36
- Day's Range
- 1.37–1.41
- 52-Week Range
- 1.17–3.90
- Volume
- 31.53K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.61
Valuation
- Market Cap
- $69.40M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 75.40
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.21
Financials (FY)
- Revenue (FY)
- $409.66K
- Net Income (FY)
- −$12.00M
- Shares Outstanding
- 49.22M
- 1-Year Return
- +15.57%
Dividend and dates
- Earnings Date
- November 12, 2026estimated
- Avg Volume
- 326.96K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, MNOV closed at $1.41, +15.57% over 1 year.
MediciNova, Inc. (MNOV) has a market capitalization of $69.40M.
In fiscal 2025, MNOV reported revenue of $409.66K.
MNOV Stock Return by Calendar Year
MediciNova, Inc. (MNOV) 10-year return: what $10,000 became
- 1 year
- $10,000 $11,557
- +15.57%
- 5 years
- $10,000 $3,811
- −61.89%
- 10 years
- $10,000 $1,997
- −80.03%
If you had invested $10,000 in MediciNova, Inc. (MNOV) 10 years ago, at the close on October 21, 2016, it would have been worth $1,997 at the close on October 21, 2026: −80.03% in total, −14.88% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +7.63% |
| 2025 | −37.62% |
| 2024 | +40.00% |
| 2023 | −26.83% |
| 2022 | −23.51% |
| 2021 | −49.05% |
| 2020 | −21.96% |
| 2019 | −17.50% |
| 2018 | +26.28% |
| 2017 | +7.30% |
| 2016 (partial year) | −8.08% |
As of October 21, 2026.
MNOV Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $409.66K | −$12.00M | −2,928.8% |
| 2024 | $0.00 | −$11.05M | — |
| 2023 | $1.00M | −$8.57M | −857.2% |
| 2022 | $0.00 | −$14.07M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $409.66K | $31.05K | −$13.28M | −$12.00M | −2,928.8% |
| 2024 | $0.00 | $0.00 | −$12.68M | −$11.05M | — |
| 2023 | $1.00M | — | −$9.90M | −$8.57M | −857.2% |
| 2022 | $0.00 | — | −$14.63M | −$14.07M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
MNOV Valuation vs Biotechnology Median
Median of 608 stocks| Metric | MNOV | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 75.40 | 13.30 | 5.7x the median |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
MediciNova CEO Provides Shareholder Update
YahooMediciNova Provides Update On Recent Topline Results Of Its Phase 2 Clinical Trial Evaluating MN-001 For Treatment Of Nonalcoholic Fatty Liver Disease And Hypertriglyceridemia Associated With Type 2 Diabetes Mellitus; At End Of The 24-Week Period, Serum Triglycerides, Liver Fat, And Body Weight Were Also Reduced In The MN-001 Group Compared With Placebo, Although These Differences Did Not Reach Statistical Significance
BenzingaMediciNova to Participate in the Maxim Growth Summit
YahooMediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles
YahooMediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints
InvestorsHubMediciNova stock tumbles on mixed Phase 2 NAFLD trial data
Yahoo
All 12 articles ↓Show fewer ↑
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
YahooMediciNova Announces Topline Results From MN-001-NATG-202, Its Phase 2 Clinical Trial Evaluating MN-001 (Tipelukast) For Treatment Of Hypertriglyceridemia And Nonalcoholic Fatty Liver Disease Associated With Type 2 Diabetes Mellitus; At Week 24, The MN-001 Group Continued To Show A Numerical Reduction From Baseline Value, Although The Difference Between The MN-001 And Placebo Groups Were Not Statistically Significant
BenzingaMediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
YahooMediciNova Completes Last Patient, Last Visit In The Double-Blind Portion Of COMBAT-ALS Phase 2B/3 Clinical Trial Evaluating MN-166 For The Treatment Of Amyotrophic Lateral Sclerosis
BenzingaRoth Capital Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $6
BenzingaMediciNova to Participate in Two Investor Conferences in September
Yahoo
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B